Volume 2.21 | Jun 11

Immune Regulation News 2.21, June 11, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Gamma Interferon Prompts Stem Cell Response to Fight Infection
Invading bacteria can be a call-to-arms, awaking the sleeping stem cells and prompting them to produce immune system cells that fight the foreign organisms. The “bugler” that awakes the stem cells in this battle is gamma interferon. [Press release from Baylor College of Medicine discussing online prepublication in Nature]

Request A Poster  
Isolate Untouched Cells for
Antigen Processing and Presentation
with EasySep®


Video – RoboSep® – Product Tour


Making Cancer Killers: Reprogramming Immune System Cells to Produce Natural Killer Cells for Cancer
A team of researchers has developed a method to produce cells that kill tumour cells in the lab and prevent tumours forming in mouse models of cancer. [Press release from Wellcome Trust Sanger Institute discussing online prepublication in Science]

Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase III Trial of Previously-Treated Patients with Metastatic Melanoma
Bristol-Myers Squibb Company announced positive results from a Phase III randomized, double blind study of ipilimumab which demonstrated that overall survival was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab. [Press release from Bristol-Myers Squibb Company discussing research presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO)]

NewLink Genetics’ HyperAcute® Immunotherapy Phase II Study Shows Promise in Disease Free and Overall Survival for Resectable Pancreatic Cancer
NewLink Genetics Corporation announced positive Phase II clinical trial data of its HyperAcute®-Pancreas cancer immunotherapy combined with standard adjuvant chemotherapy in patients with surgically resectable pancreatic cancer. [Press release from Genetic Engineering & Biotechnology News discussing research presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO)]

Interleukin-10 A Prognostic Factor In Treatment With Autologous Melanoma Vaccine
Scientists have found that interleukin-10 production in tumor cells is a possible prognostic factor in patients with advanced melanoma who are treated with autologous melanoma cell vaccine. [Press release from Kimmel Cancer Center at Jefferson discussing research presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO)]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Quiescent Hematopoietic Stem Cells are Activated by IFN-Gamma in Response to Chronic Infection
Here researchers show, using an in vivo mouse model of Mycobacterium avium infection, that an increased proportion of long-term repopulating hematopoietic stem cells proliferate during M. avium infection, and that this response requires interferon-gamma but not interferon-alpha signalling. [Nature]

Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBP(Beta) Transcription Factor
Researchers showed that among factors produced by various experimental tumors, the cytokines GM-CSF, G-CSF, and IL-6 allowed a rapid generation of myeloid-derived suppressor cells from precursors present in mouse and human bone marrow. [Immunity]

Inhibition of Lipid Antigen Presentation in Dendritic Cells by HIV-1 Vpu Interference with CD1d Recycling from Endosomal Compartments
Given that the interaction with CD1d-expressing Dendritic cells is central to the ability of natural killer T (NKT) cells to regulate immunity, these data suggest that interference with the CD1d antigen presentation pathway represents an HIV-1 strategy to evade innate cellular immune responses, and imply a role for the innate-like CD1d-restricted NKT cells in the host defense against HIV-1. [Blood]

Allosteric Inhibition of Macrophage Migration Inhibitory Factor Revealed by Ibudilast
As described herein, the phosphodiesterase (PDE) inhibitor AV411 (ibudilast; 3-isobutyryl-2-isopropylpyrazolo-[1,5-a]pyridine) and its PDE-inhibition-compromised analog AV1013 inhibit the catalytic and chemotactic functions of the proinflammatory protein, macrophage migration inhibitory factor. [Proc Natl Acad Sci U S A]

Systemically Dispersed Innate IL-13-Expressing Cells in Type 2 Immunity
Here, researchers use IL-4 and IL-13 reporter mice to track lineage-negative innate cells that arise during type 2 immunity or in response to IL-25 and IL-33 in vivo. [Proc Natl Acad Sci U S A]

Identification of an IL-27/Osteopontin Axis in Dendritic Cells and its Modulation by IFN-Gamma Limits IL-17-Mediated Autoimmune Inflammation
The results identify a previously unknown pathway by which IFN-gamma limits IL-17-mediated autoimmune inflammation through differential regulation of osteopontin and IL-27 expression in dendritic cells. [Proc Natl Acad Sci U S A]

Enzymatically Active Single Chain Caspase-8 Maintains T Cell Survival During Clonal Expansion
Here, researchers show that caspase-8-deficient T cell survival was rescued by enzymatically active, but not inactive, casp8-expressing retroviruses. [Cell Death Differ]

TLR4-Mediated Skin Carcinogenesis is Dependent on Immune and Radioresistant Cells
The results suggest that the initial release of high mobility group box-1 protein triggers a TLR4-dependent inflammatory response that leads to tumour development. [EMBO J]

Control of T Cell Reactivation by Regulatory Qa-1-Restricted CD8+ T Cells
These experiments provide new insight into a CD8+ T cell compartment that regulates the immediate reactivation of conventional T cells and natural killer T cells. [J Immunol]


Idera Pharmaceuticals Announces Preliminary Data from Phase I Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Drug Candidate for Autoimmune and Inflammatory Diseases
Idera Pharmaceuticals, Inc. announced preliminary results from a Phase I clinical trial of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for potential applications in autoimmune and inflammatory diseases. [Idera Pharmaceuticals, Inc. Press Release]

VBL Therapeutics Present Data on VB-201 for Rheumatoid Arthritis at EULAR Annual Meeting
VBL Therapeutics announced the presentation of preclinical data from the company’s lead program, VB-201, at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology. [VBL Therapeutics Press Release]

Cytheris Closes $15 Million Series D Financing
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, announced that it has completed a $15 million Series D financing. [Cytheris SA Press Release]

The Iacocca Family Foundation and Kineta Announce New Partnership on Type I Diabetes Mellitus Drug Development Program
Kineta, Inc. joined with The Iacocca Family Foundation to announce a new investment partnership to speed development of Kineta’s preclinical autoimmune drug candidate, ShK-186, and its multiple applications to treat Type I diabetes mellitus. [Kineta, Inc. Press Release]


STAR METRICS: New Way to Measure the Impact of Federally Funded Research
A new initiative–Science and Technology for America’s Reinvestment: Measuring the Effect of Research on Innovation, Competitiveness and Science, or STAR METRICS–promises to monitor the impact of federal science investments on employment, knowledge generation, and health outcomes. [National Institutes of Health, United States]

Market Withdrawal of GAMMAGARDLIQUID, Immune Globulin Intravenous (Human) 
This voluntary market withdrawal is being conducted as a precautionary measure due to an increased number of adverse event reports of allergic reactions. [Food and Drug Administration, United States]

FDA Announces Collaboration with Drugs.com
The U.S. Food and Drug Administration announced that it will collaborate with the website Drugs.com to expand access to the FDA’s consumer health information. [Food and Drug Administration, United States]

Administrative Supplements to Increase Public Awareness of Pediatric Cancers and Available Treatments and Research (NOT-CA-10-026) [National Institutes of Health, United States]

2010 Biological License Application Approvals [Food and Drug Administration, United States]

2010 Biological Device Application Approvals [Food and Drug Administration, United States]


Phacilitate Vaccine & Immunotherapy Forum 2010
June 21-23, 2010
Barcelona, Spain

Federation of Clinical Immunology Societies (FOCIS) 2010
June 24-27, 2010
Boston, United States

The Second International Conference on Regulatory T Cells and Th17 Cells and Clinical Application in Human Diseases
July 17-20, 2010
Shanghai, China

Frontiers in Immunology Research (FIRN) 2010 International Conference
July 22-26, 2010
Athens, Greece

14th International Congress of Immunology
August 22-27, 2010
Kobe, Japan

Select Biosciences 7th Annual RNAi & miRNA Europe
September 14-15, 2010
Dublin, Ireland

5th International Conference on Gene Regulation in Lymphocyte Development
October 9-14, 2010
Chania, Greece

Autumn Immunology Conference 2010
November 19-22, 2010
Chicago, United States

Cell Symposia: Influenza – Translating Basic Insights
December 2-4, 2010
Washington, D.C., United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Sr. Product Support and Training Specialist (CardianBCT)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

here  to post your career opportunities.

Have we missed an important article or publication in Immune Regulation News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Immune Regulation News: Archives  |  Events  |  Update Profile  |  Contact Us